Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study
BJOG: An International Journal of Obstetrics & Gynaecology · 2024
DOI: 10.1111/1471-0528.17803 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2024. Verfasst von Jin-Sung Yuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Postmenopause, Estrogen Replacement Therapy, Norpregnenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the association between menopausal hormonal therapy (MHT) and the risk of cardiovascular disease (CVD), according to various regimens, dosages, routes of administration and starting ages of MHT.
Design
A population‐based cohort study using the Korean National Health Insurance Services database.
Setting
Nationwide health insurance database. Population Women who reported entering menopause at an age of ≥40 years with no history of CVD in the national health examination.
Methods
The study population comprised 1 120 705 subjects enrolled between 2002 and 2019, categorised according to MHT status (MHT group, n = 319 007; non‐MHT group, n = 801 698). Main outcome measures Incidence of CVD (a composite of myocardial infarction and stroke).
Results
The incidence of CVD was 59 266 (7.4%) in the non‐MHT group and 17 674 (5.5%) in the MHT group. After adjusting for confounding factors, an increased risk of CVD was observed with the administration of tibolone (hazard ratio, HR 1.143, 95% CI 1.117–1.170), oral estrogen (HR 1.246, 95% CI 1.198–1.295) or transdermal estrogen (HR 1.289, 95% CI 1.066–1.558), compared with the non‐MHT group; the risk was based on an increased risk of stroke. The risk trends were consistent regardless of the age of starting MHT or the physicians’ specialty. Among tibolone users, a longer period from entering menopause to taking tibolone and the use of any dosage (1.25 or 2.5 mg) were linked with a higher risk of CVD, compared with non‐MHT users.
Conclusions
This nationwide cohort study demonstrated an increased risk of CVD, driven mainly by an increased risk of stroke, among tibolone and oral or transdermal estrogen users, compared with that of non‐MHT users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
- Medi-i Women's Hospital, Seoul, Republic of Korea.
ORCID-Profile: Jin-Sung Yuk, Gwang Sil Kim, Young Sup Byun, Myoung-Hwan Kim, Byung Gyu Kim
Zitieren
APA
Yuk, J. S., Kim, G. S., Byun, Y. S., Yang, S. W., Kim, M. H., Yoon, S. H., Seo, Y. S., & Kim, B. G. (2024). Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17803
Vancouver
Yuk JS, Kim GS, Byun YS, Yang SW, Kim MH, Yoon SH, et al. Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2024. doi:10.1111/1471-0528.17803
BibTeX
@article{Yuk2024,
author = {Yuk, Jin-Sung and Kim, Gwang Sil and Byun, Young Sup and Yang, Seung-Woo and Kim, Myoung-Hwan and Yoon, Sang-Hee and Seo, Yong-Soo and Kim, Byung Gyu},
title = {Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2024},
doi = {10.1111/1471-0528.17803}
}
EUVIMED